Teva Pharmaceutical Industries Limited or Intra-Cellular Therapies, Inc.: Who Invests More in Innovation?

Teva vs. Intra-Cellular: A Decade of R&D Investment

__timestampIntra-Cellular Therapies, Inc.Teva Pharmaceutical Industries Limited
Wednesday, January 1, 2014212263451488000000
Thursday, January 1, 2015877180741525000000
Friday, January 1, 2016938315302111000000
Sunday, January 1, 2017794190091848000000
Monday, January 1, 20181321669131213000000
Tuesday, January 1, 2019891248381010000000
Wednesday, January 1, 202065782137997000000
Friday, January 1, 202188845513967000000
Saturday, January 1, 2022134715000838000000
Sunday, January 1, 2023180142000953000000
Monday, January 1, 2024998000000
Loading chart...

Igniting the spark of knowledge

Innovation Investment: A Tale of Two Companies

In the competitive world of pharmaceuticals, innovation is key. Over the past decade, Teva Pharmaceutical Industries Limited and Intra-Cellular Therapies, Inc. have shown contrasting approaches to research and development (R&D) investments. From 2014 to 2023, Teva consistently outspent Intra-Cellular Therapies, with R&D expenses peaking in 2016 at over twice the amount of its competitor. However, Intra-Cellular Therapies has shown a remarkable growth trajectory, increasing its R&D spending by over 750% from 2014 to 2023. This upward trend highlights its commitment to innovation, despite being a smaller player. Meanwhile, Teva's R&D investment has seen a gradual decline, dropping by about 36% from its 2016 peak. This data provides a fascinating insight into how these companies prioritize innovation, with Intra-Cellular Therapies rapidly closing the gap in recent years.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025